



D1

(D doc)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 93/09120

(51) International Patent Classification⁵ :
C07D 487/04, 471/04 // (C07D 487/04
C07D 235:00, 209:00)
(C07D 471/04, 235:00, 221:00)
(C07D 487/04, 235:00, 223:00)

A1

(11) International Publication Number:

(43) International Publication Date:

13 May 1993 (13.05.93)

(21) International Application Number: PCT/EP92/02560

(22) International Filing Date: 3 November 1992 (03.11.92)

(30) Priority data:
9123641.4

7 November 1991 (07.11.91) GB

(71) Applicant (for all designated States except US): SMITH-
KLINE BEECHAM FARMACEUTICI S.P.A. [IT/IT];
Via Zambelletti, I-20021 Baranzate di Bollate (IT).


(72) Inventors; and

(75) Inventors/Applicants (for US only): POZZI, Ottorino [IT/
IT]; SmithKline Beecham Farmaceutici, Via Zambelletti,
I-20021 Baranzate di Bollate (IT). PINZA, Mario [IT/
IT]; Via per Cesano Boscone, 24, I-20094 Corsico (IT).
FARINA, Carlo [IT/IT]; PARINI, Carlo [IT/IT];
SmithKline Beecham Farmaceutici, Via Zambelletti, I-
20021 Baranzate di Bollate (IT). CORNAGGIA, Nico-
letta [IT/IT]; Via Val d'Ossola, 7, I-20086 Motta Visconti
(IT). PFEIFFER, Ugo, Claudio [IT/IT]; Via Raffaello
Sanzio, 31, I-20149 Milan (IT).(74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate
Patents, Great Burgh, Yew Tree Bottom Road, Epsom
Surrey KT18 5XQ (GB).(81) Designated States: AU, CA, JP, KR, US, European patent
(AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, SE).


Published

With international search report.

(54) Title: PROCESS FOR THE PREPARATION OF CONDENSED IMIDAZOLES



(I)



(II)

(57) Abstract

A process for the preparation of compounds of formula (I), wherein R¹ represents hydrogen, C₁₋₄ alkyl, CHR³CO or CHR³COOR⁴ in which R³ and R⁴ each independently represent hydrogen or C₁₋₄alkyl; R² represents hydrogen or alkyl; and n is an integer 2, 3 or 4; which process comprises cyclising a compound of formula (II), wherein R² and n defined in relation to formula (I); R⁵ represents hydrogen or a group COOR⁷ wherein R⁷ is a C₁₋₄ alkyl group or a group; and R⁶ represents a hydroxy group or a group OR⁸ wherein R⁸ represents C₁₋₄ alkyl or a benzyl group; and thereafter, as necessary, carrying out one more of the following steps: i) removing any protecting group; and ii) converting pound of formula (I) into another compound of formula (I).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

Process for the preparation of condensed imidazoles

5 The invention relates to a process for preparing certain fused imidazole derivatives and in particular for preparing chiral fused imidazole derivatives.

European Patent Application, Publication No. 0,335,483 discloses certain fused imidazole derivatives of formula (A):

10



15

wherein,

20 R^a is hydrogen, C_{1-4} alkyl, $CH(R^d)CONH(R^e)$ or $CH(R^d)COO(R^e)$ in which R^d and R^e are each hydrogen or C_{1-4} alkyl;

R^b is hydrogen, C_{1-5} alkyl or any residue R^b of an amino acid $R^bCH(NH_2)COOH$

25 R^c is hydrogen, C_{1-4} alkyl, $CONH_2$ or CO_2R^f in which R^f is hydrogen or C_{1-4} alkyl; and

m is 2, 3 or 4.

30 EP 0,335,483 also discloses a process for preparing the compounds of formula (A) which involves either:


a) reacting a compound of formula (B) with a compound of formula (C):

35

-2-



(B)




(C)

- 5 wherein R^a , R^b , R^c , and m are as defined in relation to formula (A), R^g is hydrogen and R^h is hydrogen, C_{1-4} alkyl or benzyl; or

b) cyclising a compound of formula (D):

10



(D)

- 15 where in R^a , R^b , R^c and m are as defined in relation to formula (A) and R^g and R^h are as defined in relation to formulae (B) and (C).

The compounds of formula (A) are disclosed in EP 0,335,483 as having activity as nootropic reagents.


20

EP 0,335,483 also discloses that the compounds of formula (A) can contain one or more chiral carbons. In particular it is to be noted that the bridgehead carbon of formula (A) is always a chiral carbon.

- 25 A process has now been discovered which facilitates the preparation of certain compounds of formula (A) and in particular facilitates the preparation of individual optical isomers of such compounds in which the chiral carbon is the bridgehead carbon.

- 30 Accordingly, the present invention provides a process for the preparation of compounds of formula (I):

35



(I)

WQ 93/09120.


-3-

wherein

R¹ represents hydrogen, C₁₋₄ alkyl, CHR³CONHR⁴ or CHR³COOR⁴ in which R³ and R⁴ each independently represent hydrogen or C₁₋₄ alkyl;

5 R² represents hydrogen or C₁₋₅ alkyl; and n is an integer 2, 3 or 4;

which process comprises cyclising a compound of formula (II):



15

wherein R² and n are as defined in relation to formula (I);

R⁵ represents hydrogen or a group COOR⁷ wherein R⁷ is a C₁₋₄ alkyl group or a benzyl group; and R⁶ represents a hydroxy group or a group


20 OR⁸ wherein R⁸ represents C₁₋₆ alkyl or a benzyl group; and thereafter, as necessary, carrying out one or more of the following steps:

i) removing any protecting group; and

25 ii) converting a compound of formula (I) into another compound of formula (I).

Suitably the cyclisation is effected by a cyclising reagent.

30 In certain circumstances, the cyclisation of the compound of formula (II) may provide a compound of formula (III):



-4-

wherein R^2 and n are as defined in relation to formula (I) and R^{10} is a C_{1-6} alkyl group or a group OR^7 wherein R^7 is as defined in relation to formula (II); the compound of formula (III) may then be converted into a compound of formula (I), wherein R^1 is H, by hydrogenolysis or
5 hydrolysis, the resulting compound of formula (I) may subsequently be converted into other compounds of formula (I) as desired.

Compound (III) is generally provided when the cyclising reagent is a carboxylic anhydride.

10

Accordingly, the present invention, in a further particular aspect provides a process for preparing a compound of formula (I), which process comprises hydrogenolysing or hydrolysing a compound of the above defined formula (III); and thereafter, as necessary converting the resulting
15 compound of formula (I), wherein R^1 is H, into a further compound of formula (I).

When R^6 is OH, the cyclisation of a compound of formula (II) is conveniently effected under dehydration cyclisation conditions, preferably
20 in the presence of a dehydration cyclisation reagent.

Suitable dehydration cyclisation reagents include dicyclohexylcarbodiimide or carboxylic anhydrides such as acetic anhydride.

25


When the reagent is dicyclohexylcarbodiimide, the reaction is preferably carried out in the presence of an organic base such as triethylamine, in any suitable solvent, such as acetonitrile, at any convenient temperature providing a suitable rate of formation of the required product, aptly at
30 ambient temperature.

When the reagent is a carboxylic anhydride such as acetic anhydride, the reaction may be carried out in any suitable solvent, but conveniently using acetic anhydride itself as solvent, and at any convenient
35 temperature providing a suitable rate of formation of the product, suitably at the reflux temperature of the solvent and preferably in the presence of anhydrous sodium acetate.

- Suitable means for hydrogenolysing any compound of formula (III) include conventional catalytic hydrogenolysis techniques. Suitable means for hydrolysing any compound include conventional hydrolysis techniques, such as mild acid hydrolysis, for example by using an acidic resin such as Amberlite IR 120.

- When R_6 is a group OR_8 , the cyclisation is preferably effected by use of a strong base such as n-butyl lithium or potassium t-butoxide.
- 10 The cyclisation of a compound of formula (II), wherein R_6 is a group OR_8 , may be suitably carried out in an aprotic solvent, such as tetrahydrofuran or toluene: for example when potassium t-butoxide is the strong base the reaction is conveniently carried out in toluene, at ambient temperatures: when n-butyl lithium is the strong base the reaction is conveniently
- 15 carried out in tetrahydrofuran at low to ambient temperature, generally at a temperature within the range of from -80°C to -30°C , for example in the range of from -70 to -65°C .
- 20 A compound of the abovedefined formula (II), may be prepared by reacting a compound of formula (IV):

25



- wherein R^2 , R^6 and n are as defined in relation to formula (II), with a reagent capable of converting a $-\text{CO.NH}_2$ group into an $-\text{NH}_2$ group, and thereafter, if required, carrying out one or more of the following optional steps:

- i) protecting and thereafter, as necessary, de-protecting any group;
- 35 ii) converting a compound wherein R^5 is H into a compound wherein R^5 is COOR^7 , wherein R^7 is as defined in relation to formula (II); and

-6-

iii) converting any group R^6 which represents OR^8 into a group R^6 which represents hydroxy.

5 Suitable reagents capable of converting a $-CO.NH_2$ group into an $-NH_2$ group include bis(trifluoroacetoxy)iodosobenzene or a source of hypochlorite ion, such as sodium hypochlorite.

10 The conditions for the reaction between the compound of formula (IV) and the reagent capable of converting a $-CO.NH_2$ group into an $-NH_2$ group will of course depend upon the particular reagent used, but generally the appropriate conventional conditions for the particular reagent chosen will be used: when the reagent is bis(trifluoro- acetoxy)iodosobenzene the reaction is carried out in any suitable solvent, such as aqueous acetonitrile, preferably in an inert atmosphere such as nitrogen, at any
15 convenient temperature which provides a suitable rate of formation of the desired product, conveniently at a low to ambient temperature, for example in the range of from 0° - $5^\circ C$: when the reagent is a source of hypochlorite ions, such as sodium hypochlorite, the reaction is carried out in any suitable solvent, generally an aqueous solvent, conveniently water,
20 at any convenient temperature providing a suitable rate of formation of the required product, such as in the range of $0^\circ C$ to $100^\circ C$, generally in the range of from $0^\circ C$ to room temperature, for example $0^\circ C$ to $5^\circ C$; preferably the sodium hypochlorite reaction is carried out in the presence of sodium hydroxide.

25 The conversion of a compound wherein R^5 is H into a compound wherein R^5 is $COOR^7$ may be carried out using a conventional chemical procedures, for example the conversion of a compound wherein R^5 is H into a compound wherein R^5 is $COOR^7$ is provided by treating the
30 appropriate compound with a compound of formula (V):



wherein R^7 is as defined in relation to formula (II) and X represents a
35 leaving group, such as a halogen atom, for example a chlorine atom. Usually, the appropriate compound is present in salted form, for example alkali metal salted form, such as a sodium salted form, prepared by treating the appropriate compound with a base, for example an alkali


-7-

metal hydroxide, such as sodium hydroxide.

The reaction between the appropriate compound and the compound of formula (V) may be carried out in any suitable solvent, generally an aqueous solvent, conveniently water, at low to medium temperature, generally in the range of 0°C to + 40°C, suitable from 0°C to 5° or from 5°C to ambient temperature.

The conversion of any group R⁶ which represents OR⁸ into a group R⁶ which represents hydroxy may be carried out using the appropriate conventional procedure, for example by using conventional hydrolysis methods, for example treatment with an alkali metal hydroxide, such as sodium hydroxide.

A compound of formula (IV) may be prepared by aminating a compound of formula (VI):



(VI)

25 wherein R², R⁶ and n are as defined in relation to formula (II) and R⁹ is a C₁₋₆ alkyl group; and thereafter, if required,

i) protecting and thereafter, as necessary, deprotecting any group;


30 ii) converting any group R⁶ which represents OR⁸ into a group R⁶ which represents hydroxy.

The amination of compound (VI) may be effected using conventional amination conditions, for example by using concentrated aqueous ammonia at any temperature providing a convenient rate of formation of the required product, conveniently at ambient temperature.

A compound of formula (VI) may be prepared by reacting a compound of

-8-

formula (VII):



(VII)

- 10 wherein R^9 and n are as defined in relation to formula (VI), with a compound of formula (VIII):



- 15 wherein R^2 and R^6 are as defined in relation of formula (II) and X is a leaving group such as halide; and thereafter, if required carrying out one or more of the following optional steps:

- 20 i) protecting and thereafter, as necessary, de-protecting any group;
- ii) converting any group R^6 which represents OR^8 into a group R^6 which represents hydroxy.

- 25 Suitably the compound of formula (VII) is present in an activated form, for example a salted form such as a sodium salted form, provided by treating the compound of formula (VII) with a salting agent such as sodium hydride.


- 30 The reaction between a compound of formula (VII) and a compound of formula (VIII) may be carried out using analogous conditions to those described in *Berichte*, 44, 1333 (1911).

- 35 The compounds of formula (VII) are known compounds or they may be prepared by analogous procedures to those used to prepare known compounds, for example the compounds of formula (VII) wherein n is 2 are known, commercially available compounds.

A compound of formula (II) may also be prepared by reacting a compound

of formula (IX):

5



(IX)

10 wherein R^5 and n are as defined in relation to formula (II), with a compound of the hereinbefore defined formula (VIII); and thereafter, if required, carrying out one or more of the following optional steps:


- 15 i) protecting and thereafter, as necessary, de-protecting any group;
- ii) converting one group R^5 into another group R^5 .

20 The reaction between the compounds of formulae (VIII) and (IX) may be carried out using conditions analogous to those used in the reaction between compounds of formulae (VII) and (VIII).

25 The compounds of formula (IX) are known compounds or they may be prepared using methods analogous to those used to prepared known compounds, for example the methods disclosed in Heterocycles, 14, 1245 (1980).

Alternatively, a compound of formula (IX) may be prepared by reacting a compound of formula (X):

30



35

(X)

wherein n is as defined in relation to formula (I), with a reagent capable of

-10-

converting a carboxyl group into a group $-NHR^5$ and thereafter, as required, carry out one or more of the following optional steps:

- i) removing any protecting group, in particular any
5 benzylcarboxylate group;
- ii) converting one group R^5 into another group R^5 .

10 A suitable reagent capable of converting a carboxyl group into a group $-NHR^5$ is diphenylphosphorylazide in the presence of triethylamine and, as required, an appropriate alcohol. The reaction conditions for the reaction between the compound of formula (X) and the reagent capable of
15 converting a carboxyl group into a group $-NHR^5$ will in general be the appropriate conventional conditions for the particular reagent chosen; for example when the reagent is a Curtius reagent such as diphenylphosphorylazide the reaction is suitably effected under the Curtius reaction conditions such as those disclosed in Synthesis, 294 (1985).

20 An alcohol is generally required when R^5 represents a group $-COOR^7$: the particular alcohol required is that dictated by the value of R^7 in the required compound of formula (IX): thus the alcohol is an alcohol of formula R^7OH .

25 Protecting groups may be removed using the appropriate conventional procedure, for example a benzyl carboxylate group may be removed using conventional catalytic hydrogenolysis using hydrogen and a Pd/C catalyst.



30 Suitable conversions of one group R^5 into another group R^5 include those mentioned hereinbefore.

The compounds of formula (X) are known compounds or they may be prepared in accordance with procedures used to prepare known compounds, for example those disclosed in Synthesis, 294 (1985). In
35 particular it is to be noted that the compounds of formula (X) wherein n is 2 may be prepared by conventional benzylation of the naturally occurring amino acid pyroglutamic acid. The R and S isomers of pyroglutamic acid are readily available in resolved form.


Suitable protecting groups for any of the groups mentioned herein and methods for removing such protecting groups are those used conventionally in the art, for example a suitable amino protecting group is the group COR¹⁰ as defined above.

The preparation of a resolved form ((R) or (S)) isomer of a compound of formula (I) may suitably be obtained by the sequence of reactions summarised below in Schemes 1 to 5:


10

Scheme (1)15 **Scheme (2):****Scheme (3):**

20

**Scheme (4):**

25

**Scheme (5):**

30

In the abovementioned schemes the compounds of formulae (I), (II), (III), (IV), (VI), (VII), (IX) and (X) are as defined above and the reaction conditions for each reaction are as defined hereinbefore.

Each of the abovementioned Schemes (1), (2), (3), (4) and (5) form a further specific aspect of the present invention.

In Schemes (1) and (3) it is particularly advantageous if the cyclisation of

-12-

(II) to (I) is effected using dicyclohexylcarbodiimide.

In Schemes (2), (4) and (5) it is particularly advantageous if the cyclisation of (II) to (III) is effected using a carboxylic anhydride.

5

In Scheme (4) it is particularly advantageous if variable R^6 in the compounds of formulae (VI) and (IV) is -O-t-butyl.

The following Examples illustrate the present invention but do not limit it
10 in any way.

-13-

Example 1**(R,S)-5-Benzylloxycarbonylamino-2-pyrrolidinone**

- 5 A mixture of 5-ethoxy-2-pyrrolidinone (20 g) and benzyl carbamate (25.8 g) were stirred at 85°C until fusion. A catalytic amount of 4-toluenesulfonic acid was added and stirring at 85°C was continued for six hours, while distilling off the ethanol formed.
- 10 After cooling, the reaction mixture was chromatographed over silica gel (dichloromethane - methanol 95:5) to yield 26.7 g of the title compound, as a white solid melting at 90-92°C.
- 15 ¹H-NMR (DMSO-d₆ delta: 8.10 (bs; 1H; CONH); 7.90 (bd; J = 9Hz, 1H, CHNHCO); 7.35 (s; 5H, Ph); 5.20 (c.a.; 1H, CH); 5.05 (s; 2H, CH₂Ph); 2.50 - 1.50 (c.a.; 4H, CH₂CH₂).
- MS (E.I., 70 eV), m/z: 234 (M+.), 190 (M-CO₂), 150 (M-C₄H₆NO), 143 (M-C₇H₇), 128 (M-C₇H₆O), 108 (C₇H₈O), 91 (C₇H₇), 84 (C₄H₆NO).

20

Example 2**Ethyl (R,S)-5-benzylloxycarbonylamino-2-oxo-1-pyrrolidine-**
25 **acetate**

- To an ice cold solution of (R,S)-5-benzylloxycarbonylamino-2-pyrrolidinone (8 g) in acetonitrile (400 ml), sodium hydride (55-60% oil dispersion) (1.5 g) was added portionwise. Stirring was continued for 1 hour, then a
- 30 solution of ethyl bromoacetate (6.3 g) in acetonitrile was added dropwise, keeping the internal temperature between 0 and 5°C.

- After stirring for 4 hours at room temperature, the reaction mixture was heated at 50°C for 1 hour. The solvent was removed under vacuum and
- 35 the residue was partitioned between ethyl acetate and water. The organic layer was washed with a saturated solution of sodium hydrogen carbonate and water, dried (Na₂SO₄) and evaporated under vacuum to give 9 g of the title compound, as an oil, R_f = 0.33 (silica gel plates, dichloromethane -

-14-

methanol 95:5).

¹H-NMR (CDCl₃), delta: 7.35 (s, 5H, Ph); 5.85 (bd, J = 8.5Hz, 1H, NH); 5.50 (c.a., 1H, CH); 5.10 (s, 2H, CH₂Ph); 4.15 (q, J = 7.5Hz, 2H, CH₂CH₃); 4.10 and 3.95 (ABq, J = 14Hz, 2H, NHCH₂CO); 2.75-1.75 (c.a., 4H, CH₂CH₂); 1.22 (t, J = 7.5Hz, 3H, CH₂CH₃).

MS (E.I., 70 eV), m/z: 275 (M-C₂H₅O), 247 (M-C₃H₅O₂), 228 (M-C₇H₇), 185 (M-C₈H₇O₂), 170 (M-C₈H₈NO₂), 96 (C₅H₆NO), 91 (C₇H₇).

Example 3

(R,S)-5-Benzyloxycarbonylamino-2-oxo-1-pyrrolidineacetic acid

To an ice cold solution of ethyl (R,S)-5-benzyloxycarbonylamino-2-oxo-1-pyrrolidineacetate (8.5 g) in methanol (64 ml), a solution of potassium hydroxide 85% (2 g) in methanol (43 ml), was added dropwise. The solution was stirred at room temperature for six hours, the solvent was removed under vacuum, the residue was dissolved in water and adjusted to pH 1 with 20% hydrochloric acid.

The precipitate was collected and dried to give 6.4 g of the title compound, as a white powder melting at 139-141°C.

¹H-NMR (DMSO-d₆), delta: 7.98 (bd, J = 9Hz, 1H, NH); 7.35 (s, 1H, Ph); 5.28 (c.a., 1H, CH); 5.06 (s, 2H, CH₂Ph); 4.06 and 3.56 (ABq, J = 17Hz, 2H, NHCH₂O); 2.50-1.80 (c.a., 4H, CH₂CH₂).

MS (E.I., 70 eV), m/z: 201 (M-C₇H₇), 157 (M-C₈H₇O₂), 151 (C₈H₉NO), 141 (M-C₈H₉NO), 108 (C₇H₈O), 96 (C₅H₆NO), 91 (C₇H₇).

Example 4

Ethyl (R,S)-5-amino-2-oxo-1-pyrrolidineacetate

A mixture of ethyl (R,S)-5-benzyloxycarbonylamino-2-oxo-

-15-

- 5 1-pyrrolidineacetate (3 g), ethanol (60 ml) and 10% palladium on carbon (0.3 g) was hydrogenated (20°C, ambient pressure) for one hour. The catalyst was filtered off and the solvent was evaporated to yield 1.4 g of the title compound as an oil, $R_f = 0.25$ (silica gel plates, ethyl acetate-acetone-methanol 6:3:1).

$^1\text{H-NMR}$ (CDCl_3), δ : 4.60 (c.a., 1H, CH); 4.15 (q, $J = 7\text{Hz}$, 2H, CH_2CH_3); 4.13 - 3.95 (ABq, $J = 20\text{Hz}$, 2H, NCH_2CO); 2.50-1.50 (c.a., 4H, CH_2CH_2); 1.80 (s, 2H, NH_2); 1.22 (t, $J = 7\text{Hz}$, 3H, CH_2CH_3).

- 10 MS (E.I., 70 eV), m/z : 185 (M-H) $^+$, 170 (M-NH $_2$), 141 (M-C $_2\text{H}_5\text{O}$), 113 (M-C $_3\text{H}_5\text{O}_2$), 99 (M-C $_4\text{H}_7\text{O}_2$), 84 (C $_4\text{H}_6\text{NO}$).

15 Example 5

(R,S)-5-Amino-2-oxo-1-pyrrolidineacetic acid hydrochloride

- 20 A mixture of (R,S)-5-benzyloxycarbonylamino-2-oxo-1-pyrrolidine acetic acid (2.6 g), methanol (78 ml), 2N hydrochloric acid (4.5 ml) and 10% palladium on carbon (0.3 g) was hydrogenated (20°C, ambient pressure) for 30 minutes.

- 25 The catalyst was filtered off, the solvent was evaporated and the solid residue was triturated with diisopropyl ether to yield 1.3 g of the title compound as a white solid melting at 140-141°C.

$^1\text{H-NMR}$ (DMSO-d_6), δ : 9.00 (bs, 4H, NH_3+COOH); 5.00 (c.a., 1H, CH); 4.15 (s, 2H, NCH_2CO); 2.90-2.00 (c.a., 4H, CH_2CH_2).

- 30 MS (E.I., 70 eV), m/z : 141 (M-NH $_3$), 123 (M-H $_2\text{O}$, NH $_3$), 96 (C $_5\text{H}_6\text{NO}$).

Example 6**(R,S)-Dihydro-1-benzyloxycarbonyl-1H-pyrrolo[1,2-a]-imidazole-2,5(3H,6H)-dione**

5

A mixture of (R,S)-5-benzyloxycarbonylamino-2-oxo-1-pyrrolidineacetic acid (6.1 g), acetic anhydride (61 ml) and anhydrous sodium acetate (1.7 g) was refluxed for one hour. The solvent was evaporated under vacuum, the residue was triturated with water (50 ml) and collected, to give 4.4 g of the

10

title compound melting at 110-111°C.

¹H-NMR (CDCl₃), delta: 7.40 (s, 5H, Ph); 5.60 (t; J = 6Hz, 1H, CH); 5.33 (s, 2H, CH₂Ph); 4.35 and 3.66 (ABq, J = 17Hz, 2H, NCH₂CO); 3.00-1.90 (c.a., 4H, CH₂CH₂).

15

MS (E.I., 70 eV), m/z: 274 (M+.), 167 (M-C₇H₆O), 139 (M-C₈H₇O₂), 91 (C₇H₇), 84 (C₄H₆NO).

20 **Example 7****(R,S)-Dihydro-1H-pyrrolo[1,2-a]imidazole-2,5-(3H,6H)-dione**

A mixture of (R,S)-dihydro-1-carbobenzyloxy-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione (4 g), methanol (120 ml) and 10% palladium on carbon (0.4 g), was hydrogenated (20°C, ambient pressure) for one hour. The catalyst was filtered off and the solvent was evaporated under vacuum, to give the crude title compound as a solid, melting at 130-133°C. Crystallization from isopropyl alcohol gave 1.2 g of the pure title

30

compound as a white powder, melting at 152-154°C.

Example 835 **(R,S)-Dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione**

To a mixture of (R,S)-5-amino-2-oxo-1-pyrrolidineacetic acid hydrochloride (0.2 g), acetonitrile (60 ml) and triethylamine (0.1 g), a solution of

-17-

- dicyclohexylcarbodiimide (0.2 g) in acetonitrile (8 ml) was added dropwise. The solution was stirred for 24 hours, the precipitate was filtered off and the solvent evaporated under vacuum. The solid residue was chromatographed over silica gel (ethyl acetate-acetone-methanol 6:3:1) to yield 80 mg of the title compound as a white solid, melting at 151-153°C.

Example 9**10 (R,S)-Dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione**

- To a solution of ethyl (R,S)-5-amino-2-oxo-1-pyrrolidineacetate (0.5 g) in anhydrous toluene (10 ml), potassium tert-butoxide (0.3 g) was added and stirring was continued for three hours. Then more potassium tert-butoxide (0.3 g) was added and after 1.5 hours the mixture was neutralized with 1N hydrochloric acid. The separated aqueous layer was passed through a column of cation exchanger Amberlite IR 120 (4 g) and evaporated. The residue was chromatographed over silica gel (ethyl acetate - acetone - methanol 6:3:1) to yield 80 mg of the title compound as a white solid, melting at 149-151°C.

Example 10**25 (R,S)-Dihydro-1-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione**

- To a solution of ethyl (R,S)-5-amino-2-oxo-1-pyrrolidineacetate (1 g) in anhydrous tetrahydrofuran (20 ml), 1.6 M butyllithium in n-hexane (3.4 ml) was added dropwise, keeping the temperature between -70 and -65°C. After one hour the temperature was allowed to rise to 0°C and the reaction mixture was neutralized with 1N hydrochloric acid. The mixture was evaporated under vacuum and the residue was chromatographed over silica gel (ethyl acetate - acetone - methanol 6:3:1) to yield 0.2 g of the title compound.

35

Example 11**(R)-1-Benzylloxycarbonyl-5-benzylloxycarbonylamino-2-pyrrolidinone**

5 A stirred suspension of N-benzylloxycarbonyl-D-pyroglyutamic acid (25 g) in freshly distilled dry toluene (125 ml) was flushed with nitrogen and treated with diphenylphosphoryl azide (20.5 ml). The mixture was heated to 80°C, and keeping this temperature, a solution of triethylamine (13.1
10 ml) in toluene (62.5 ml) was added dropwise during 3 h. To the clear solution, benzyl alcohol (10.7 ml) in toluene (62.5 ml) was added quickly and the mixture was allowed to reach room temperature. The crystalline product precipitated on standing. After filtration it was washed thoroughly with cold toluene and dried under vacuum, affording the title
15 compound (18.61 g) as a white solid, m.p. 149-152°C; $[\alpha]_D^{20} = +31.2$ (c=1, DMF).

¹H-NMR (CDCl₃), delta: 7.35 (s, 10H, Ph); 5.72 (c.a., 2H, CH-NH); 5.25 (s, 2H, COOCH₂); 5.07 (s, 2H, NHCOOCH₂); 2.00-3.10 (c.a., 4H,
20 CH₂CH₂).

MS (E.I., 70 eV), m/z: 368 (M+), 277 (M-C₇H₇), 260 (M-C₇H₈O), 217 (M-C₈H₉NO₂), 127 (C₁₅H₁₅NO₂), 107 (C₇H₇O), 91 (C₇H₇), 84 (C₄H₆NO).

25

Example 12**(R)-5-Amino-2-pyrrolidinone hydrochloride**

30 A solution of (R)-1-benzylloxycarbonyl-5-benzylloxycarbonyl-amino-2-pyrrolidinone (18.61 g.) in methanol/dioxane (4/1) (2.5 l) and 10% hydrochloric acid (22.3 ml) was hydrogenated (20°C, ambient pressure) over 10% Pd/C (2.05 g). The reaction was allowed to proceed for 0.5 h, then the catalyst was removed by suction filtration through a Celite pad.
35 Evaporation of the filtrate afforded the title compound (6.8 g) as a yellow solid, $[\alpha]_D^{20} = +11.8^\circ$ (c=0.17, H₂O/dioxane = 1/1).

¹H-NMR (DMSO-d₆), delta: 8.70 (bs, 3H, NH₃⁺); 8.33 (bs, 1H, CONH);

4.88 (bs, 1H, CH); 2.80-1.80 (c.a., 4H, CH₂CH₂).

MS (E.I., 70 eV), m/z: 100 (M⁺), 84 (M-NH₂).

5

Example 13

(S)-5-Benzylloxycarbonylamino-2-pyrrolidinone

- 10 To an ice cold solution of (R)-5-amino-2-pyrrolidinone hydrochloride (6.7 g) in water (1.4 l), benzyl chloroformate (12 ml) and 0.5 N NaOH (82 ml) were added. The reaction mixture was stirred at 2-7°C for 1.5 h. Then, 0.5 N sodium hydroxide was added portionwise to maintain the pH between 7 and 9 while the mixture was allowed to warm to room temperature. After 15 2.5 h, more benzyl chloroformate (12 ml) was added quickly and stirring was continued for 2 hours at room temperature. The mixture was extracted with dichloromethane (500 ml x 3). The organic layer was dried (Na₂SO₄) and evaporated under reduced pressure. The oily residue was trituated with diisopropyl ether to afford 8.5 g of the title compound as a 20 white solid, m.p. 127-129°C; [α]_D²⁰ = -79.6 (c=1, MeOH).

¹H-NMR (CDCl₃), delta: 7.35 (s, 5H, Ph); 6.50 (bs, 1H, CONH); 5.70 (bd, J = 7Hz, 1H, CHNHCO); 5.40 (c.a., 1H, CH); 5.15 (s, 2H, CH₂Ph); 2.75-1.75 (c.a., 4H, CH₂CH₂).

25

MS (E.I., 70 eV), m/z: 234 (M⁺), 190 (M-CO₂), 143 (M-C₇H₇), 126 (M-C₇H₈O), 108 (C₇H₈O), 91 (C₇H₇), 84 (C₄H₆NO).

Example 14

30

Ethyl (R)-5-benzyloxycarbonylamino-2-oxo-1-pyrrolidineacetate

- The procedure of example 2 was repeated starting from (R)-5-benzyloxy-carbonylamino-2-pyrrolidinone (9.24 g) to afford the title 35 compound (11.8 g) as an oil. Rf: 0.33 (silica gel plates, dichloromethane-methanol 95:5).

¹H-NMR (CDCl₃), delta: 7.35 (s, 5H, Ph); 5.85 (bd, J = 8.5HZ, 1H, NH);

-20-

5.50 (c.a., 1H, CH); 5.10 (2H, CH_2Ph); 5.15 (q, $J = 7.5\text{Hz}$, 2H, CH_2CH_3); 4.10 and 3.95 (ABq, $J = 14\text{Hz}$, 2H, NCH_2CO); 2.75-1.75 (c.a., 4H, CH_2CH_2); 1.22 (t, $J = 7.5\text{Hz}$, 3H, CH_2CH_3).

- 5 MS (E.I., 70 eV), m/z : 320 (M^+), 275 ($\text{M}-\text{C}_2\text{H}_5\text{O}$), 247 ($\text{M}-\text{C}_3\text{H}_5\text{O}_2$), 185 ($\text{M}-\text{C}_8\text{H}_7\text{O}_2$); 170 ($\text{M}-\text{C}_8\text{H}_8\text{NO}_2$), 91 (C_7H_7).

Example 15

10

(R)-5-Benzyloxycarbonylamino-2-oxo-1-pyrrolidineacetic acid

- 15 The procedure of example 3 was repeated starting from ethyl (R)-5-benzyloxycarbonylamino-2-oxo-1-pyrrolidineacetate (11.5 g) to afford the title compound (7.44 g) as a solid foam. Rf: 0.59, silica gel plates, butanol - acetic acid - water 4:1:1).

- 20 $^1\text{H-NMR}$ (DMSO-d_6), δ : 7.95 (bd, $J = 9\text{Hz}$, 1H, NH); 7.35 (s, 5H, Ph); 5.28 (c.a., 1H, CH); 5.06 (s, 2H, CH_2Ph); 4.06 and 3.56 (ABq, $J = 17\text{Hz}$, 2H, NCH_2CO); 2.50-1.80 (c.a., 4H, CH_2CH_2).

MS (E.I., 70 eV), m/z : 201 ($\text{M}-\text{C}_7\text{H}_7$), 151 ($\text{C}_8\text{H}_9\text{NO}_2$), 142 ($\text{M}-\text{C}_9\text{H}_{10}\text{O}_2$), 108 ($\text{C}_7\text{H}_8\text{O}$), 91 (C_7H_7).

25

Example 16

(S)-Dihydro-1-benzyloxycarbonyl-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione

30

The procedure of example 6, was repeated starting from (R)-5-benzyloxycarbonylamino-2-oxo-1-pyrrolidineacetic acid (7.33 g) to afford 4 g of the title compound as a brown solid, m.p. = 123-127°; $[\alpha]^{20}_{\text{D}} = +53.8^\circ$, ($c=1$, DMF).

35

$^1\text{H-NMR}$ (CDCl_3), δ : 7.40 (s, 5H, Ph); 5.60 (t; $J = 6\text{Hz}$, 1H, CH); 5.33 (s, 2H, CH_2Ph); 4.40 and 3.70 (ABq, $J = 17\text{Hz}$, 2H, NCH_2CO); 3.00-1.90 (c.a., 4H, CH_2CH_2).

MS (E.I., 70 eV), m/z: 274 (M+.), 168 (M-C₇H₆O), 139 (M-C₈H₇O₂), 91 (C₇H₇), 84 (C₄H₆NO).

5

Example 17**(R)-Dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione**

10 The procedure of example 7, was repeated starting from (R)-dihydro-1-benzoyloxycarbonyl-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione (4 g) to afford the title compound (1.15 g) as a white solid, m.p. 197-200°; $[\alpha]_D^{20} = -39.8^\circ$, (c=0.43, MeOH).

15 ¹H-NMR (DMSO-d₆), delta: 8.68 (bs; 1H, NH); 5.25 (t, J = 4Hz, 1H, CH); 3.80 and 3.40 (ABq, J = 15Hz, 2H, NCH₂CO); 2.90-1.55 (c.a.; 4H, CH₂CH₂).

20 MS (E.I., 70 eV), m/z: 140 (M+.), 111 (M-CHO), 97 (M-CHNO); 84 (C₃H₄N₂O).

Example 18**25 Benzyl (S)-5-carbethoxy-2-oxo-1-pyrrolidineacetate**

A mixture of ethyl L-pyroglytamate [E. Fischer et al., Berichte 44, 1333 (1911)] (13.1 g), tetrabutylammonium bromide (10.36 g) and potassium carbonate (45 g) in acetonitrile (100 ml) was stirred at 20°C for 1 hour.

30 Benzyl 2-bromoacetate (25 ml) was added and the temperature was raised to 60°C. Stirring was continued for 2.5 hours, maintaining the temperature at 60-65°C. After cooling the insoluble material was filtered off and washed with diethyl ether.

35 The combined filtrates were evaporated under reduced pressure. The oily residue was dissolved in ethyl acetate (100 ml) and washed with 10% hydrochloric acid, a saturated solution of sodium hydrogen carbonate and water. The organic layer was dried and evaporated, the oily residue was

-22-

chromatographed over silica gel (eluting first with dichloromethane then with dichloromethane/methanol 8:2). The appropriate fractions were collected and evaporated to give 18.5 g of title compound as a brown oil; b.p. 240-250°C at 0.6 mmHg (partial decomposition); $[\alpha]_D^{20} = -36.1^\circ$, (c=5; CH₂Cl₂).

¹H-NMR (CDCl₃), delta: 7.37 (s, 5H, Ph); 5.18 (s, 2H, CH₂Ph); 4.70 and 3.84 (ABq, J = 17Hz, 2H, NCH₂COO); 4.45 (c.a., 1H, CH); 4.22 (q, J = 6Hz, 2H, CH₂CH₃); 2.75-2.00 (c.a., 4H, CH₂CH₂); 1.28 (t, J = 6Hz, 3H, CH₂CH₃).

MS (E.I., 70 eV), m/z: 305 (M+), 232 (M-C₃H₅O₂), 214 (M-C₇H₇), 170 (M-C₈H₇O₂), 156 (M-C₉H₉O₂), 142 (C₆H₈NO₃), 98 (C₅H₈NO), 96 (C₅H₆NO), 91 (C₇H₇).

Example 19

(S)-5-Carboethoxy-2-oxo-1-pyrrolidineacetic acid

A mixture of benzyl (S)-5-carboethoxy-2-oxo-1-pyrrolidine-acetate (6.5 g, 21 mmol) and 10% Pd on charcoal (0.65 g) in ethyl acetate (65 ml) was hydrogenated at room temperature and ambient pressure. After 6 hours the catalyst was filtered off and the solvent was evaporated under vacuum, affording 4.6 g of the title compound as a yellowish oil, $[\alpha]_D^{20} -36.1^\circ$, (c=5, CH₂Cl₂).
Dicyclohexylammonium salt: m.p. 115°C.

¹H-NMR (CDCl₃), delta: 8.43 (bs, 1H, COOH); 4.65 and 3.87 (ABq, J = 18Hz, 2H, NCH₂COO); 4.48 (c.a., 1H, CH); 4.25 (q, J = 6Hz, 2H, CH₂CH₃); 2.70-2.00 (c.a., 4H, CH₂CH₂); 1.30 (t, J = 6Hz, 3H, CH₂CH₃).

MS (E.I., 70 eV), m/z: 215 (M+), 197 (M-H₂O), 169 (M-C₂H₆O), 156 (M-C₂H₃O₂), 142 (M-C₃H₅O₂), 96 (C₅H₆NO).

Example 20**(S)-5-Carbamoyl-2-oxo-1-pyrrolidineacetic acid**

- 5 A solution of (S)-5-carbethoxy-2-oxo-1-pyrrolidineacetic acid (22.1 g) in concentrated ammonia solution (170 ml) was stirred at room temperature for 3 h. After evaporation under vacuum, the oily residue was dissolved in water (150 ml) and stirred with cation exchange resin Amberlite IRA 120 (30 ml) for 2 hours. The resin was filtered off and the solution was
- 10 evaporated under reduced pressure, affording the title compound (17.5 g) as a deiquescent amorphous solid, $[\alpha]^{20}_D = -14.5^\circ$, (c=5, H₂O). Dicyclohexylammonium salt: m.p. 187-190°C.

- 15 ¹H-NMR (DMSO-d₆), delta: 8.27 (bs, 1H, COOH); 7.92 and 7.15 (bs, 2H, CONH₂); 4.20 (c.a., 1H, CH); 4.10 and 3.35 (ABq, J = 17Hz, 2H, NCH₂CO); 2.40-1.70 (c.a., 4H, CH₂CH₂).

MS (E.L., 70 eV), m/z: 185 (M-H)⁺, 168 (M-H₂O), 142 (M-CH₂NO), 126 (M-C₂H₄O₂), 96 (C₅H₆NO), 84 (C₄H₆NO).

20

Example 21**(S)-5-Amino-2-oxo-1-pyrrolidineacetic acid hydrochloride**

- 25 A solution of (S)-5-carbamoyl-2-oxo-1-pyrrolidineacetic acid (14.7 g) and [bis(trifluoroacetoxy)iodo]benzene (34.5 g) in water (100 ml) and acetonitrile (200 ml) was stirred at room temperature, under nitrogen, for 4 hours. Acetonitrile was removed under reduced pressure, the aqueous
- 30 layer was washed with diethyl ether (2 x 50 ml) and evaporated under reduced pressure. The residue was dissolved in 10% hydrochloric acid (50 ml) and evaporated. The residue was triturated with acetone to afford the title compound (7.5 g) as a white solid, m.p. > 250°C; $[\alpha]^{20}_D = +2.5^\circ$, (c=1, water).

35

- ¹H-NMR (DMSO-d₆), delta: 9.75 (bs, 4H, NH₃⁺ COOH); 5.00 (c.a., 1H, CH); 4.15 (s, 2H, NCH₂CO); 2.90-2.00 (c.a., 4H, CH₂CH₂).

Example 22**(R)-Dihydro-1-benzoyloxycarbonyl-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione**

5 A solution of (S)-5-carbamoyl-2-oxo-1-pyrrolidineacetic acid (1 g, 5.4 mmol) and [bis(trifluoroacetoxy)iodo]benzene (2.72 g, 6.2 mmol) in acetonitrile/water 1:1 (26 ml) was stirred at room temperature for 2.5 hours. Acetonitrile was added to obtain a clear solution and stirring was
10 continued for 1.5 hours. The solution was evaporated, the residue was dissolved in water (20 ml) and washed with diethyl ether (2 x 15 ml). To the aqueous solution, sodium hydrogen carbonate (2.25 g) and benzyl chloroformate (1.9 ml) were added and the mixture was stirred at room temperature overnight. The solution was washed with dichloromethane (2
15 x 25 ml), acidified, and extracted with dichloromethane (2 x 25ml). Drying (Na_2SO_4) and evaporation of the organic solution afforded crude (S)-5-benzoyloxycarbonylamino-2-oxo-1-pyrrolidineacetic acid (0.4 g). This compound was dissolved in acetic anhydride (5 ml) containing sodium acetate (150 mg) and the mixture refluxed for 1 hour. After evaporation
20 the residue was triturated with water to yield 0.14 g of the title compound as a brown solid, m.p. 118-128°C [α]_D = -52.2° (c=1, DMF).

Example 23**(S)-Dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione**

25 A mixture of (S)-5-amino-2-oxo-1-pyrrolidineacetic acid hydrochloride (7 g), triethylamine (5.05 ml) and dicyclohexylcarbodiimide (7.4 g) in acetonitrile (1 l) was stirred under nitrogen for 24 hours. The mixture was
30 evaporated under reduced pressure, the residue was dissolved in water (50 ml), and the insoluble material filtered off. The aqueous filtrate was treated with cation exchanger Amberlite IRA 120 (40 ml) and anion exchanger Amberlite IR 68 (40 ml) under stirring for 1.5 hours. The resin
35 was filtered off, the aqueous solution was evaporated under reduced pressure and the residue was triturated from isopropanol and recrystallized from isopropanol, to yield 1.5 g of the title compound as a white crystalline solid m.p. 197-202°C [α]_D²⁰ = +41.6°, (c=0.38,

MeOH).

Example 24

5

(S)-Dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione

The procedure of example 7 was reported starting from (S)-dihydro-1-benzyloxycarbonyl-1H-pyrrolo[1,2-a]imidazole-2, 5(3H,6H)-dione (0.14 g) to afford the title compound (0.03 g) as a white solid, m.p. 198-202°C; [alpha]²⁰_D = +42.8°, (c=0.26, MeOH).

10

Example 25

15

(R)-t-Butyl-5-carbomethoxy-2-oxo-1-pyrrolidineacetate

A solution of (5-R)-methyl pyroglutamate (122g) in 1.75l of acetonitrile was cooled to 0°-5°C and 55-60% sodium hydride (34.1g) was added portionwise. Stirring was continued for 1.5 hours and t-butyl bromoacetate (175.5g) was added dropwise. The ice bath was removed and stirring continued for 1.5 hours. After evaporation of the solvent, the residue was dissolved in ethyl acetate, the organic phase was washed with a saturated solution of NaHCO₃, dried, and evaporated to dryness, to give the title compound (182.1g, 83%) as a yellow oil; [alpha]²⁰_D = +42.3° (c = 5, CH₂Cl₂).

20

25

¹H-NMR (CDCl₃), deltaH: 4.53 - 3.60 (ABq, J = 17.5Hz, 2H, NCH₂O); 4.45 (m, 1H, NCHCO); 2.6 - 2.0 (m, 4H, CH₂CH₂); 1.45 (s, 9H, t-butyl).

30

MS (E.I., 70 eV, 1.5 mA): m/z 201(M-C₄H₈), 156 (M-C₅H₉O₂), 184 (C₄H₉O).

Example 26**(S)-t-Butyl-5-carbomethoxy-2-oxo-1-pyrrolidineacetate**

- 5 The title compound was prepared using the same procedure described in Example 25 starting from (5-S)-methyl pyroglutamate; $[\alpha]^{20}_D = -38.9$ (c=5, CH₂Cl₂).

10 ¹H-NMR (CDCl₃), δ H: 4.53 - 3.50 (ABq, J = 17.5Hz, 2H, NCH₂O); 4.45 (m, 1H, NHCO); 2.6 - 2.0 (m, 4H, CH₂CH₂); 1.45 (s, 9H, t-butyl)

MS (E.I., 70 eV, 1.5 mA): m/z 201 (M - C₄H₈), 156 (M - C₅H₉O₂), 184 (C₄H₉O).

15

Example 27**(R)-t-Butyl-5-carbamoyl-2-oxo-1-pyrrolidineacetate**

- 20 A mixture of (5-R)-t-butyl-5-carbomethoxy-2-oxo-1-pyrrolidineacetate (182.1g) and 32% ammonium hydroxide (900 ml) was stirred at room temperature for 1.5 hours.

25 The excess of ammonia was removed under vacuum, the solution neutralised with 37% hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried over sodium sulphate and evaporated to dryness to give the title compound 104.7 g (61.1%) as a white powder, m.p. 132-135°C; $[\alpha]^{20}_D = +32.4^\circ$ (c = 5, CH₂Cl₂).

30 ¹H-NMR (DMSO - d₆), δ H: 7.55 - 7.12 (bs, 2H, CONH₂); 4.25 - 3.40 (ABq, J = 17.5Hz, 2H, NCH₂CO); 4.15 (m, 1H, NHCO); 2.40 - 1.75 (m, 4H, CH₂CH₂); 1.45 (s, 9H, t-butyl).

35 MS (E.I., 70 eV, 1.5 mA): m/z = 198 (M - CNH₂O), 185 (M - C₄H₉), 142 (M - CNH₂O - C₄H₈).

Example 28**(S)-t-Butyl-5-carbamoyl-2-oxo-1-pyrrolidineacetate**

- 5 The title compound was prepared using the same procedure described in Example 27 starting from (5-S)-t-butyl-5-carbomethoxy-2-oxo-1-pyrrolidinacetate; m.p. 128-129°C; $[\alpha]_D^{20} = -31.3^\circ$ (c = 5, CH₂Cl₂).

- 10 ¹H-NMR (DMSO - d₆), δ H: 7.60 - 7.17 (bs, 2H, CONH₂); 4.25 - 3.40 (ABq, J = 17.5, 2H, NCH₂CO); 4.15 (m, 1H, NHCO); 2.40 - 1.75 (m, 4H, CH₂CH₂); 1.45 (s, 9H, t-butyl).

MS (E.I., 70 eV, 1.5 mA): m/z = 198 (M - CNH₂O), 185 (M - C₄H₉), 142 (M - CNH₂O - C₉H₈).

15

Example 29**(R)-5-Amino-2-oxo-1-pyrrolidineacetic acid, hydrochloride**

- 20 A solution of 5.7% sodium hypochlorite (570 ml) was added dropwise to a solution of sodium hydroxide pellets (51.9 g) in water (1.05 l), maintaining the temperature at 0 - 5°C. To this solution, (5-R)-t-butyl-5-carbamoyl-2-oxo-1-pyrrolidinacetate (104.7g), was added portionwise maintaining the
- 25 same temperature, and then for 15 minutes at 55-60°C. After cooling to 0-5°C, 37% of hydrochloric acid (145 ml) was added to pH2. The solution was evaporated under vacuum and the residue triturated with methanol.

- 30 The solvent was removed to give the title compound (69.8 g, 83%) as a white solid; $[\alpha]_D^{20} = -2.3^\circ$ (c=1, H₂O)

¹H-NMR (DMSO - d₆), δ H: 9.5 (bs, 1H, COOH); 4.95 (m, 1H, NHCO); 4.15 (s, 2H, NCH₂CO); 2.85 - 2.0 (m, 4H, CH₂CH₂).

- 35 MS (E.I., 70 eV, 1.5 mA): m/z 141 (M - NH₃), 123 (M - H₂O, NH₃).

Example 30**(S)-5-Amino-2-oxo-1-pyrrolidineacetic acid, hydrochloride**

- 5 The title compound was prepared using the same procedure described in Example 29, starting from (5-S)-t-butyl-5-carbamoyl-2-oxo-1-pyrrolidinacetate.

10 Example 31**(S)-Dihydro-1-acetyl-1H-pyrrolo[1,2a]imidazole-2,5(3H, 6H)-dione**

- 15 A mixture of (5-R)-5-amino-2-oxo-1-pyrrolidinacetic acid hydrochloride (69.8g), anhydrous sodium acetate (29.4 g) and acetic anhydride (700 ml), was refluxed for 1.5 hours. The brown mixture was allowed to cool to room temperature and then evaporated to dryness.

- 20 The residue was treated under stirring with ethyl acetate and a saturated solution of ammonium sulphate.

- The organic layer was dried over sodium sulphate and evaporated under vacuum to give the title compound (54g, 82.5%) as an oil; m.p. 82-83°C; $[\alpha]_D^{20} = +159^\circ$ (c = 0.1, MeOH)

- 25 $^1\text{H-NMR}$ (CDCl_3), δ_{H} : = 5.65 (m, 1H, NCHN); 4.45 - 3.75 (ABq, J = 17.5Hz, 2H, NCH₂CO); 3.1 - 2.0 (m, 4H, CH₂CH₂); 2.50 (s, 3H, COCH₃).

- 30 MS (E.I., 70 eV, 1.5 mA): m/z = 154 (H - CO), 139 (H - C₂H₃O).

Example 32**(R)-Dihydro-1-acetyl-1H-pyrrolo[1,2a]imidazole-2,5(3H,6H)-dione**

- 35 The title compound was prepared using the same procedure described in Example 31, starting from (5-S)-5-amino-2-oxo-1-pyrrolidinacetic acid hydrochloride; m.p. 81-82°C, $[\alpha]_D^{20} = -153.9^\circ$ (c = 0.1, MeOH).

¹H-NMR (CDCl₃), δ _H: 5.65 (m, 1H, NCHN); 4.615 - 3.75 (ABq, J = 17.5 Hz, 2H, NCH₂CO); 3.1 - 2.0 (m, 4H, CH₂CH₂); 2.50 (s, 3H, COCH₃).

5 **MS** (E.I., 70 eV, 1.5 mA): m/z = 154 (H - CO), 139 (H - C₂H₃O).

Example 33

10 **(R)-Dihydro-1H-pyrrolo[1,2a]imidazole-2,5(3H,6H)-dione**

A mixture of (7a-S)-dihydro-1-acetyl-1H-pyrrolo[1,2a]imidazole-2,5-(3H, 6H)-dione (54 g), Amberlite IR 120 (54 g) in water (540 ml), was stirred at room temperature for 24 hours. The resin was collected on a Buckner

15 funnel and the dark filtrate was evaporated under vacuum, the residue was triturated with isopropanol to give the title compound.

Crystallisation from isopropanol gave the pure compound (15.5 g) as a white crystalline solid, m.p. 197-199°C, $[\alpha]^{20}_D = -39.2^\circ$ (c = 1,

20 MeOH).

¹H-NMR (DMSO-d₆) δ _H: 8.63 (bs, 1H, NH); 5.23 (t, J = 5 Hz, 1H, CH₂CH); 3.8 - 3.45 (ABq, J = 17 Hz, 2H, NCH₂CO); 2.90 - 1.60 (m, 4H, CH₂CH₂).

25 **MS** (E.I., 70 eV, 1.5 mA): m/z = 140 (M⁺), 97 (M - CONH).

Example 34

30 **(S)-Dihydro-1H-pyrrolo[1,2a]imidazole-2,5(3H,6H)-dione**

The title compound was prepared using the same procedure described in Example 33 starting from (R)-dihydro-1-acetyl-1H-pyrrolo[1,2a]imidazole-

35 2,5-(3H,6H)-dione; m.p. 197-199°C, $[\alpha]^{20}_D = +39.9^\circ$ (c = 1, MeOH)

¹H-NMR (DMSO-d₆) δ _H: 8.63 (bs, 1H, NH); 5.23 (t, J = 5 Hz, 1H, CH₂CH); 3.8 - 3.45 (ABq, J = 17 Hz, 2H, NCH₂CO); 2.90 - 1.60 (m, 4H,

-30-


CH_2CH_2).

MS (E.I., 70 eV, 1.5 mA): $m/z = 140$ (M^+), 97 ($M - \text{CONH}$).

Claims

1. A process for the preparation of compounds of formula (I):

5



10


wherein

R¹ represents hydrogen, C₁₋₄ alkyl, CHR³CONHR⁴ or CHR³COOR⁴ in which R³ and R⁴ each independently represent hydrogen or C₁₋₄ alkyl; R² represents hydrogen or C₁₋₅ alkyl; and n is an integer 2, 3 or 4;

15

which process comprises cyclising a compound of formula (II):

20



- 25 wherein R² and n are as defined in relation to formula (I); R⁵ represents hydrogen or a group COOR⁷ wherein R⁷ is a C₁₋₄ alkyl group or a benzyl group; and R⁶ represents a hydroxy group or a group OR⁸ wherein R⁸ represents C₁₋₆ alkyl or a benzyl group; and thereafter, as necessary, carrying out one or more of the following steps:

30

i) removing any protecting group; and


ii) converting a compound of formula (I) into another compound of formula (I).

35

2. A process according to claim 1, wherein the cyclisation is effected by a cyclising reagent.

-32-

3. A process according to claim 1 or claim 2, wherein the cyclising reagent is a carboxylic anhydride.
4. A process according to claim 3, wherein the cyclisation of the compound of formula (II) provides a compound of formula (III):



(III)


- 15 wherein R^2 and n are as defined in relation to formula (I) and R^{10} is a C_{1-6} alkyl group or a group OR^7 wherein R^7 is as defined in relation to formula (II); and wherein the compound of formula (III) is converted into a compound of formula (I), wherein R^1 is H, by hydrogenolysis or hydrolysis, the resulting compound of formula (I) subsequently being converted into other compounds of formula (I) as desired.

20

5. A process according to claim 1, wherein R^6 is OH and the cyclisation of a compound of formula (II) is effected under dehydration cyclisation conditions in the presence of a dehydration cyclisation reagent.
- 25 6. A process according to claim 5, wherein the dehydration cyclisation reagents include dicyclohexylcarbodiimide or carboxylic anhydrides such as acetic anhydride.
7. A process according to claim 1, wherein R_6 is a group OR_g and the cyclisation is effected by use of a strong base such as n-butyl lithium or potassium t-butoxide.
- 30


8. A process according to claim 1, for the preparation of a resolved form ((R) or (S)) isomer of a compound of formula (I) which process comprises the sequence of reactions summarised below in Schemes 1 to 5:
- 35

Scheme (1):



5

Scheme (2):




10 Scheme (3):



Scheme (4):

15



Scheme (5):

20



and wherein the compounds of formulae (I), (II), (III), (IV), (VI), (VII), (IX) and (X) are as defined above and the reaction conditions for each reaction are as defined hereinbefore.

25

9. A process according to schemes (1) and (3) of claim 8, wherein the cyclisation of (II) to (I) is effected using dicyclohexylcarbodiimide.

10. A process according to schemes (2), (4) and (5) of claim 8, wherein the cyclisation of (II) to (III) is effected using a carboxylic anhydride.

11. A process according to scheme (4) of claim 8, wherein variable R⁶ in the compounds of formulae (VI) and (IV) is -O-t-butyl.

12. A process according to claim 1, for the preparation of a compound selected from the list consisting of:

(R,S)-dihydro-1H-pyrrolo[1,2-a]imidazole-2,5-(3H,6H)-dione;

-34-

(R)-dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione;and

(S)-dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione.

5

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C07D487/04;
(C07D471/04, 235:00, 221:00) (C07D487/04, 235:00, 223:00) // (C07D487/04, 235:00, 209:00)
C07D471/04;**II. FIELDS SEARCHED**Minimum Documentation Searched⁷

Classification Symbols

Classification System

Int.Cl. 5

C07D

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸**III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹**Category¹⁰Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages¹²Relevant to Claim No.¹³

A

EP, A, 0 335 483 (ISF)
4 October 1989
cited in the application
see claim 4

1

¹⁰ Special categories of cited documents:

- ^{"A"} document defining the general state of the art which is not considered to be of particular relevance
- ^{"E"} earlier document but published on or after the international filing date
- ^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- ^{"O"} document referring to an oral disclosure, use, exhibition or other means
- ^{"P"} document published prior to the international filing date but later than the priority date claimed

^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.^{"&"} document member of the same patent family**IV. CERTIFICATION**

Date of the Actual Completion of the International Search

11 FEBRUARY 1993

International Searching Authority

EUROPEAN PATENT OFFICE

Date of Mailing of this International Search Report

26.02.93

Signature of Authorized Officer

ALFARO FAUS I.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

EP 9202560
SA 66848

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 11/02/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0335483	04-10-89	AU-A- 2969289	10-08-89
		AU-A- 7947991	12-09-91
		JP-A- 1246281	02-10-89
		US-A- 5053422	01-10-91
		US-A- 5130319	14-07-92
<hr/>			

EP FORM 1007

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82